Mills J F, Tudehope D
Department of Neonatology, Royal Children's Hospital, Flemington Road, Parkville, Victoria, Australia, 3052.
Cochrane Database Syst Rev. 2001;2001(1):CD002060. doi: 10.1002/14651858.CD002060.
Phototherapy is used to treat newborn infants with hyperbilirubinaemia. Fibreoptic phototherapy is a new mode of phototherapy which is reported to lower serum bilirubin (SBR) while minimising disruption of normal infant care.
To evaluate the efficacy of fibreoptic phototherapy.
The standard search strategy of the Cochrane Collaboration was used including searches of the Cochrane Controlled Trials Register, MEDLINE, EMBASE and discussion with experts in the field.
Randomised or quasi-randomised controlled trials evaluating the efficacy of fibreoptic phototherapy in the management of newborn infants with hyperbilirubinaemia.
Thirty-one studies were identified of which 24 met inclusion criteria. They evaluated the efficacy of fibreoptic phototherapy in a number of different clinical situations and patient populations.
Fibreoptic phototherapy was more effective at lowering SBR than no treatment but less effective than conventional phototherapy (percentage change in SBR after 24 hours of treatment: WMD -10.7%, 95%CI -18.14, -3.26 and WMD 3.59%, 95%CI 1.27, 5.92 respectively). Fibreoptic phototherapy was equally as effective as conventional phototherapy in preterm infants and when two fibreoptic devices were used simultaneously (change in SBR after 24 hours of treatment: WMD 1.7%, 95%CI -2.65, 6.05 and change in SBR per day over whole treatment period: WMD 2.82%, 95%CI -1.84, 7.48 respectively). A combination of fibreoptic and conventional phototherapy was more effective than conventional phototherapy alone (duration of phototherapy: WMD -12.51 hr, 95%CI -16.00, -9.02, meta-analysis affected by heterogeneity). No conclusion can be made on the superiority of one fibreoptic device over another as the two studies comparing them (one favouring BiliBlanket, the other finding no difference) did not contain a common outcome measure.
REVIEWER'S CONCLUSIONS: Fibreoptic phototherapy has a place in the management of neonatal hyperbilirubinaemia. It is probably a safe alternative to conventional phototherapy in term infants with physiological jaundice. No trials have been identified which support the widely-held view that fibreoptic devices interfere less with infant care or impact less on parent-child bonding.
光疗用于治疗新生儿高胆红素血症。光纤光疗是一种新的光疗模式,据报道其可降低血清胆红素(SBR),同时将对正常婴儿护理的干扰降至最低。
评估光纤光疗的疗效。
采用Cochrane协作网的标准检索策略,包括检索Cochrane对照试验注册库、MEDLINE、EMBASE,并与该领域专家进行讨论。
评估光纤光疗对新生儿高胆红素血症治疗效果的随机或半随机对照试验。
共识别出31项研究,其中24项符合纳入标准。这些研究评估了光纤光疗在多种不同临床情况和患者群体中的疗效。
光纤光疗在降低SBR方面比不治疗更有效,但比传统光疗效果差(治疗24小时后SBR的百分比变化:加权均数差为-10.7%,95%置信区间为-18.14,-3.26;加权均数差为3.59%,95%置信区间为1.27,5.92)。在早产儿中以及同时使用两个光纤设备时,光纤光疗与传统光疗效果相当(治疗24小时后SBR的变化:加权均数差为1.7%,95%置信区间为-2.65,6.05;整个治疗期间每天SBR的变化:加权均数差为2.82%,95%置信区间为-1.84,7.48)。光纤光疗与传统光疗联合使用比单纯传统光疗更有效(光疗持续时间:加权均数差为-12.51小时,95%置信区间为-16.00,-9.02,荟萃分析受异质性影响)。由于比较两种光纤设备的两项研究(一项支持蓝光毯,另一项未发现差异)没有共同的结局指标,因此无法得出一种光纤设备优于另一种的结论。
光纤光疗在新生儿高胆红素血症的治疗中占有一席之地。对于足月生理性黄疸婴儿,它可能是传统光疗的一种安全替代方法。尚未发现有试验支持广泛持有的观点,即光纤设备对婴儿护理的干扰较小或对亲子关系的影响较小。